Evidence map›Paper›PMID 39471757›Full record

ArticleThe International journal on drug policy2024

Co-designing the INHSU Prisons Hepatitis C Advocacy Toolkit using the Advocacy Strategy Framework.

Shelley J Walker, Olivia Dawson, Yumi Sheehan, Lok B Shrestha, Andrew R Lloyd, Julia Sheehan, Nonso B Maduka, Joaquin Cabezas, Nadine Kronfli, Matthew J Akiyama and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The International journal on drug policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. EuroHePP: The European Toolkit to Strengthen National Responses for the Elimination of Viral Hepatitis in Prisons.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shelley J WalkerNational Drug Research Institute, Curtin University, Perth, Australia; Burnet Institute, Melbourne, Australia; Public Health and Preventative Medicine, Monash University, Melbourne, Australia. Electronic address: shelley.walker@curtin.edu.au.
Olivia DawsonThe International Network on Health and Hepatitis in Substance Users (INHSU).
Yumi SheehanThe Kirby Institute, University of New South Wales (UNSW), Sydney, Australia.
Lok B ShresthaThe Kirby Institute, University of New South Wales (UNSW), Sydney, Australia; School of Biomedical Sciences, University of New South Wales (UNSW), Sydney, Australia.
Andrew R LloydThe Kirby Institute, University of New South Wales (UNSW), Sydney, Australia.
Julia SheehanThe hepatitis C Trust, London, England, United Kingdom.
Nonso B MadukaBensther Development Foundation, Enugu, Nigeria.
Joaquin CabezasGastroenterology and Hepatology Department, University Hospital Marques de Valdecilla, Santander, Spain; Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL) Santander, Spain.
Nadine KronfliDepartment of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Québec, Canada; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
Matthew J AkiyamaDepartment of Medicine, Albert Einstein College of Medicine / Montefiore Medical Centre, New York, USA.
INHSU Prisons

Funding

Leveraging community health workers to improve SARS-CoV-2 testing and mitigation among criminal justice-involved individuals accessing a corrections-focused community-based organizationR01MD016744 · NIMHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Matthew Akiyama · 2021 to 2026
$3.5M
Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject DrugsDP2DA053730 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2021 to 2021
$2.5M
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants LivingR00DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2020 to 2022
$747k
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants Living with Hepatitis C-The HCV-ACCELERATE TrialK99DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI AKIYAMA, MATTHEW · 2017 to 2018
$369k
NIDA NIH HHS DP2 DA053730NIDA NIH HHS K99 DA043011NIDA NIH HHS R00 DA043011NIMHD NIH HHS R01 MD016744
6 · The paper itself

Abstract

backgroundThe World Health Organization (WHO) has established targets to eliminate the hepatitis C virus (HCV) by 2030. Prisons are a key focus of elimination efforts, however, access to HCV services in prisons remains low globally. With the aim of increasing advocacy efforts to help address this gap, the International Network on Health and Hepatitis in Substance Users (INHSU) Prisons, developed a Prisons Hepatitis C Advocacy Toolkit.

methodsToolkit development involved a co-design process to ensure advocacy resources met end-user needs. A scoping study was conducted, involving a web-based survey and in-depth interviews, to understand advocacy resource needs of key stakeholders from countries of different socio-economic strata. Data were analysed, and suggested advocacy resources were mapped onto the Advocacy Strategy Framework with the audiences resources are targetting and the changes they aim to influence. Advocacy resources were co-developed and validated by interview participants before incorporation into the web-based platform.

resultsSurvey responses (n = 181) and interview data (n = 25) highlighted several barriers to enhancing HCV services in prisons globally, and an understanding that advocacy efforts are needed to bring about this change. Advocacy resources were suggested for influencing three key audiences: policymakers/funders, implementers, and community. Thereafter, a suite of 20 de novo tools were co-developed with key stakeholders including case studies of evidence-based models of HCV care, policy briefs, HCV infographics, and fact sheets about how to leverage funding and build advocacy campaigns. Findings underscore the importance of capitalising on the knowledge and expertise of potential end-users, to ensure Toolkit resources are context-specific and match their needs.

conclusionThe Toolkit holds promise for progressing the WHO elimination goals by increasing advocacy efforts for enhanced prison HCV services globally. The co-design of Toolkit resources with potential end-users has increased its potential accessibility, acceptability, and inclusivity for a globally diverse audience.

Indexed as

Hepatitis CPrisonsHealth Services AccessibilityHumansPatient AdvocacyStakeholder ParticipationSurveys and QuestionnairesAdvocacyAdvocacy strategyHepatitis C eliminationHepatitis C virusPeople who inject drugsPrisons

Identifiers

PMID39471757
PMCPMC12860404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.